Инфекции, вызываемые вирусом папилломы человека: литература
Bonnez W et al: A randomized, double-blind, placebo-controlled trial of systemically administered alpha-, beta-, or gamma-interferon in combination with cryotherapy for the treatment of condyloma acuminatum. J Infect Dis 171:1081, 1995
Bonnez W et al: Current and future approaches to the treatment of condylomata acuminata (anogenitaJ warts), in Principles and Practice of Infectious Diseases Updates, GL Mandell et al. (eds). New York, Churchill Livingstone, 1996, vol 4, no 2
Bosch FX et al: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87:796, 1995
Carter JJ et al: Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 172:11, 1995
Frisch M et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337:1350, 1997
Galloway DA Is vaccination against human papillomavirus a possibility? Lancet 351(Suppl 3):22, 1998
Hagensee ME et al: Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 176:625, 1997
Ho GYF et al: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365, 1995
Ho GY et al: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423, 1998
Kjaer SK et al: Human papillomavirus.the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 65:601, 1996
Northfelt DW et al: Anal neoplasia. Pathogenesis, diagnosis, and management. Hematol Oncol Clin North Am 10:1177, 1996
Orth G, Zur Hausen H: General features: Infections of the anogenital tract, in Encyclopedia of Virology. 1994, pp 1013.1026
Reichman RC, Bonnez W: Papillomaviruses, in Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th ed., GL Mandell et al. (eds). New York, Churchill Livingstone, 1995
Rose RC et al: Human papillomavirus type 11 (HPV-11) virus-like particles (VLPs) induce the formation of neutralizing antibodies and detect genital HPV-specific antibodies in human sera. J Gen Virol 75:2075, 1994
Schiffman MH: Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 186:55, 1994
Schiffman MH: The epidemiology of cervical carcinogenesis. Cancer 76:1888, 1995
Suzich JA et al: Systemic immunization with papillomavirus LI protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553, 1995
Wideroff L et al: Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women. J Infect Dis 174:937, 1996
